29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
New guidance from the Small Business Administration (SBA) sheds light on questions that arise in the...
Read More >
In response to COVID-19-related disruption, the Construction Leadership Council (CLC) is promoting t...
Read More >
Not since the Great Recession of 2008 has the homebuilding industry faced a challenge like COVID-19....
Read More >
As many of you know, an employer does not have to offer COBRA health insurance coverage to an employ...
Read More >
On September 24, 2019, the U.S. Department of Labor (DOL) announced its final rule updating the earn...
Read More >
The U.S. Department of Labor (DOL) issued three opinion letters on January 7, 2020—one addressing t...
Read More >